What is the duration of treatment for Multi-Drug Resistant (MDR) T.B.?& x20; - MP CHO -2019 (Shift-2)

MP CHO -2019 (Shift-2)

Medical Surgical Nursing

Easy

Appeared in: MP CHO -2019 (Shift-2)

Explanation

18-24 months.
Multi-Drug Resistant Tuberculosis (MDR-TB) is defined as TB that is resistant to at least isoniazid and rifampin, the two most powerful first-line anti-TB drugs.
Treatment for MDR-TB requires the use of second-line drugs, which are often less effective, more toxic, and must be taken for a much longer duration.
The conventional or 'longer' regimen for MDR-TB, as recommended by national programs and WHO guidelines for complex cases, typically lasts for 18 to 20 months, and can extend up to 24 months depending on the patient's response.
This extended duration is necessary to ensure all resistant bacteria are eliminated and to prevent relapse.

Option B: This duration is generally longer than the standard recommended regimen for most MDR-TB cases. While some extremely complex or extensively drug-resistant (XDR-TB) cases might require treatment approaching this length, it is not the standard for MDR-TB.
Option C: This is the standard duration of treatment for drug-susceptible tuberculosis, not MDR-TB. The regimen for drug-susceptible TB is typically 2 months of an intensive phase (HRZE) followed by 4 months of a continuation phase (HR).
Option D: While the treatment for MDR-TB is indeed at least 12 months, this option is too vague. The option '18-24 months' provides a more specific and accurate timeframe for the standard longer regimen. Newer shorter regimens may last 9-11 months, but 'at least 12 months' is not the most precise answer.

Clinical Relevance

Nursing practice connection: Knowing Treatment duration for Multi-Drug Resistant Tuberculosis (MDR-TB) helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Managing MDR-TB is a significant public health challenge. Nurses play a vital role in ensuring treatment adherence through Directly Observed Therapy (DOT), which is crucial to prevent treatment failure and the emergence of even more resistant strains (XDR-TB).
Nurses must be vigilant in monitoring for the severe adverse effects of second-line TB drugs, which can include hearing loss (aminoglycosides), kidney damage, psychiatric disturbances (cycloserine), and peripheral neuropathy (linezolid). Early detection and management are key to patient safety and treatment completion.
What if? If a patient on an MDR-TB regimen shows a positive sputum culture after 6 months of treatment, it signifies a poor response or treatment failure. The nursing action would be to immediately report this to the physician, facilitate collection of a repeat specimen for culture and Drug Susceptibility Testing (DST), and prepare the patient for a potential change in their treatment regimen, which may involve adding new drugs or extending the duration.

How to Approach the Question

First, identify the core of the question: it asks for the treatment duration of a specific disease, Multi-Drug Resistant (MDR) TB.
This is a factual recall question. Access your knowledge about tuberculosis treatment guidelines.
Differentiate between the treatment for drug-susceptible TB and drug-resistant TB. Recall that drug-resistant forms require significantly longer treatment.
Evaluate the given options. '6-8 months' is the duration for drug-susceptible TB, so it can be eliminated.
Compare the remaining options. '18-24 months' is the well-established standard duration for the conventional, longer MDR-TB regimen. '24-30 months' is too long, and 'At least 12 months' is correct but not as specific.
Select the most precise and standard answer, which is '18-24 months'.

Concept Tested & Keywords

Concept Tested: Treatment duration for Multi-Drug Resistant Tuberculosis (MDR-TB)
Stem keywords: duration of treatment, Multi-Drug Resistant (MDR) T.B.
Lead-in keywords: What is

QpbOmidFrvkqzDzc_n1vXA

E6 Parks TextBook of Preventive & Social Medicine part 1 — Subpart B (pp 202-403 of 604) p. 36-38

E6 Medicine Harrison 22e Part 1 pp. 1462-1464, 1436-1438